Table 1.

Calculated IC₅₀ and EC₅₀ of 4OH tamoxifen and novel SERDs in ESR1-mutant models.

		MCF7	WT D11	F404L D10	D538G D6C	404 538 1EF	538 404 30EF	538 404 34EF	538 404 36EF	538 404 37EF
Elacestrant	IC50 (nmol/L)	12.2	3.9	5.4	27.7	20.1	23.3	34.6	nc	35.5
	EC50 (nmol/L)	16.2	10.7	6.9	59.0	24.9	27.5	46.3	67.0	57.8
Camizestrant	IC50 (nmol/L)	1.0	0.7	1.8	14.0	9.6	9.9	15.1	7.5	15.8
	EC50 (nmol/L)	2.5	2.2	2.2	28.8	10.9	12.2	20.8	47.2	25.3
4OH Tamoxifen	IC50 (nmol/L)	5.6	1.2	1.4	16.8	10.3	8.7	14.4	11.1	20.6
	EC50 (nmol/L)	8.9	7.1	3.4	37.9	14.9	11.8	21.7	95.3	46.9
Giredestrant	IC50 (nmol/L)	1.2	0.3	0.4	3.1	2.5	2.5	3.7	1.0	4.2
	EC50 (nmol/L)	1.3	0.8	0.5	6.3	3.1	3.2	4.6	9.2	6.9

Abbreviation: nc, not calculated.